2802569-31-7

Bendamustine-d4 is intended for use as an internal standard for the quantification of bendamustine (Item No. 23693) by GC- or LC-MS. Bendamustine is a purine analog and DNA alkylating agent.1 It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 μM, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 μM for both).2 It is cytotoxic to patient-derived lymphocytic leukemia (B-CLL) cells (LD50s = 6.8-8.3 mg/ml).3 Bendamustine (50 mg/kg) inhibits tumor growth by 9 and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.4 It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.1 Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.WARNING This product is not for human or veterinary use.

[1] LORENZO M LEONI. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.[J]. Clinical Cancer Research, 2008, 14 1: 309-317. DOI: 10.1158/1078-0432.ccr-07-1061
[2] S M KONSTANTINOV. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines.[J]. Journal of Cancer Research and Clinical Oncology, 2002, 90 1: 271-278. DOI: 10.1007/s00432-002-0331-8
[3] C SCHWÄNEN. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia[J]. Leukemia, 2002, 16 10: 2096-2105. DOI: 10.1038/sj.leu.2402651
[4] ZDENKA HASKOVA. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia[J]. British Journal of Haematology, 2011, 156 3: 402-404. DOI: 10.1111/j.1365-2141.2011.08829.x